{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:56:20Z","timestamp":1777114580414,"version":"3.51.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Tardive dyskinesia (TD) is a slow-onset, hyperkinetic movement disorder involving repetitive involuntary movements. It is classified as a medication-induced movement disorder that occurs in association with the use of dopamine-blocking agents\u2013most commonly, antipsychotics. It is classically understood as an unremitting process, with a few cases of reversible conditions and uncertain remission rates. Aripiprazole possesses a distinct and unique mechanism that decreases its risk compared to other antipsychotics. In this case series, we discuss three cases involving Saudi women who developed aripiprazole-induced TD; notably, all cases remitted upon aripiprazole discontinuation or dose reduction without utilizing other forms of treatment. The current literature remains limited in describing aripiprazole-induced TD, lacking a clear understanding of the development of TD following aripiprazole administration, the determined remission rate, and definite management.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1749247","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:22:26Z","timestamp":1771410146000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Reversible aripiprazole-induced tardive dyskinesia: a case series from Saudi Arabia and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Sultan M.","family":"Alshahrani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujain Mohammed","family":"Althagafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jameelah Abdullah","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina Mohammed R.","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aqeel A.","family":"Almarhoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed S.","family":"Alyahya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B2","article-title":"Medication-induced tardive dyskinesia: a review and update","volume":"17","author":"Cornett","year":"2017","journal-title":"Ochsner J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive dyskinesia: therapeutic options for an increasingly common disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000491","article-title":"Antipsychotic-induced tardive dyskinesia: update on epidemiology and management","volume":"32","author":"Widschwendter","year":"2019","journal-title":"Curr Opin Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0105-0","article-title":"Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management","volume":"7","author":"Ward","year":"2018","journal-title":"Neurol Ther"},{"key":"B6","first-page":"5","article-title":"Tardive dyskinesia: pathophysiology and animal models","volume":"61","author":"Casey","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9758\/cpn.2011.9.1.1","article-title":"Tardive dyskinesia: treatment with aripiprazole","volume":"9","author":"Kang","year":"2011","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J Neurol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jns.2018.02.011","article-title":"Genetics of tardive dyskinesia: promising leads and ways forward","volume":"389","author":"Zai","year":"2018","journal-title":"J Neurol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.16.26","article-title":"Pharmacogenetics of tardive dyskinesia: an updated review of the literature","volume":"17","author":"Lanning","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221139608","article-title":"Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan","volume":"12","author":"Mori","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"key":"B14","article-title":"Aripiprazole (abilify) and tardive dyskinesia","volume":"33","author":"Schwartz","year":"2008","journal-title":"P T"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.11l01188","article-title":"A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole","volume":"13","author":"Brown","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/ern.09.143","article-title":"Effect of second-generation antipsychotics on cognition: current issues and future challenges","volume":"10","author":"Hill","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07030469","article-title":"Aripiprazole-induced tardive dyskinesia: the role of tamoxifen","volume":"164","author":"Evcimen","year":"2007","journal-title":"Am J Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108089591","article-title":"A case of aripiprazole and tardive dyskinesia","volume":"23","author":"Abbasian","year":"2009","journal-title":"J Psychopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-5215.2011.00559.x","article-title":"Aripiprazole-induced tardive dyskinesia treated with quetiapine: a case report","volume":"23","author":"Tomruk","year":"2011","journal-title":"Acta Neuropsychiatr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01290.x","article-title":"Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature","volume":"37","author":"Ono","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.10.036","article-title":"Aripiprazole-induced tardive dyskinesia in patients with schizophrenia: a case report of twins","volume":"197","author":"She","year":"2017","journal-title":"Schizophr Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e73269","DOI":"10.7759\/cureus.73269","article-title":"Aripiprazole-induced orofacial dyskinesia in a young male: a case report","volume":"16","author":"Godhania","year":"2024","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.03.023","article-title":"Courses of aripiprazole-associated tardive dyskinesia: report of two cases","volume":"33","author":"Wang","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31819a4bd5","article-title":"Tardive dyskinesia due to aripiprazole: report of 2 cases","volume":"29","author":"Lungu","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412461058","article-title":"Aripiprazole induced tardive dyskinesia-accruing evidence","volume":"47","author":"Alexander","year":"2013","journal-title":"Aust N Z J Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00281","article-title":"Tardive dyskinesia after aripiprazole treatment that improved with tetrabenazine, clozapine, and botulinum toxin","volume":"10","author":"Aguilar","year":"2019","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852900014632","article-title":"Aripiprazole-related tardive dyskinesia","volume":"11","author":"Maytal","year":"2006","journal-title":"CNS Spectr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108098145","article-title":"Aripiprazole-induced rabbit syndrome: a case report","volume":"24","author":"Caykoylu","year":"2010","journal-title":"J Psychopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2174\/1574886310666150921104343","article-title":"Tardive dyskinesia and covert dyskinesia with aripiprazole: a case series","volume":"11","author":"Patra","year":"2016","journal-title":"Curr Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.7916\/D8MS3R8C","article-title":"Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic","volume":"4","author":"Zutshi","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for the management of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J Neurol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.19cs12983","article-title":"A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia","volume":"81","author":"Caroff","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1361322","article-title":"Antipsychotic-induced tardive dyskinesia: from biological basis to clinical management","volume":"17","author":"Salem","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.9758\/cpn.2014.12.1.69","article-title":"A case of aripiprazole induced tardive dyskinesia in a neuroleptic-na\u00efve patient with two years of follow up","volume":"12","author":"Goyal","year":"2014","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/PRA.0000000000000101","article-title":"Determining whether a definitive causal relationship exists between aripiprazole and tardive dyskinesia and\/or dystonia in patients with major depressive disorder: part 1","volume":"21","author":"Preskorn","year":"2015","journal-title":"J Psychiatr Pract"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7031245","article-title":"A case of aripiprazole-induced tardive dyskinesia with dramatic evolution","volume":"2016","author":"Heitzmann","year":"2016","journal-title":"Case Rep Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000096","article-title":"Movement disorders induced by the \u201catypical\u201d antipsychotic aripiprazole","volume":"22","author":"Selfani","year":"2017","journal-title":"Neurologist"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e65663","DOI":"10.7759\/cureus.65663","article-title":"Atypical antipsychotic-induced tardive dyskinesia in a middle-aged schizophrenic patient: a case report","volume":"16","author":"Mulla","year":"2024","journal-title":"Cureus"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1749247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:22:27Z","timestamp":1771410147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1749247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":38,"alternative-id":["10.3389\/fpsyt.2026.1749247"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1749247","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1749247"}}